218 related articles for article (PubMed ID: 27273894)
21. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.
Rotar Z; Hočevar A; Rebolj Kodre A; Praprotnik S; Tomšič M;
Clin Rheumatol; 2015 Oct; 34(10):1787-93. PubMed ID: 26345633
[TBL] [Abstract][Full Text] [Related]
22. Factors Associated With Treatment Pathways in Early Axial Spondyloarthritis: A Multistate Analysis of the 10-Year Follow-Up of the DESIR Cohort.
Portier E; Chevret S; Walter-Petrich A; Ruyssen-Witrand A; Dougados M; Moltó A
J Rheumatol; 2024 Apr; 51(4):368-377. PubMed ID: 38359943
[TBL] [Abstract][Full Text] [Related]
23. Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea.
Jeong H; Eun YH; Kim IY; Kim H; Ahn JK; Lee J; Koh EM; Cha HS
Korean J Intern Med; 2018 Mar; 33(2):407-416. PubMed ID: 27729625
[TBL] [Abstract][Full Text] [Related]
24. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
Lindström U; Bengtsson K; Olofsson T; Di Giuseppe D; Glintborg B; Forsblad-d'Elia H; Jacobsson LTH; Askling J
Ann Rheum Dis; 2021 Nov; 80(11):1445-1452. PubMed ID: 34130984
[TBL] [Abstract][Full Text] [Related]
25. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
[TBL] [Abstract][Full Text] [Related]
26. High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis.
de Wolff L; Arends S; Brouwer E; Bootsma H; Spoorenberg A
Arthritis Res Ther; 2023 Oct; 25(1):202. PubMed ID: 37848964
[TBL] [Abstract][Full Text] [Related]
27. Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA.
Atzeni F; Sarzi-Puttini P; Sebastiani M; Panetta V; Salaffi F; Iannone F; Carletto A; Foti R; Gremese E; Govoni M; Marchesoni A; Favalli E; Gorla R; Ramonda R; Ferraccioli G; Lapadula G;
Clin Exp Rheumatol; 2019; 37(4):649-655. PubMed ID: 30767865
[TBL] [Abstract][Full Text] [Related]
28. Drug maintenance of a second tumor necrosis factor alpha inhibitor in spondyloarthritis patients: A real-life multicenter study.
Krajewski F; Andras L; Pereira-Gillion C; Goupille P; Salliot C
Joint Bone Spine; 2019 Nov; 86(6):761-767. PubMed ID: 31326602
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.
Stober C; Ye W; Guruparan T; Htut E; Clunie G; Jadon D
Rheumatology (Oxford); 2018 Jan; 57(1):158-163. PubMed ID: 29077973
[TBL] [Abstract][Full Text] [Related]
30. Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort.
Yahya F; Gaffney K; Hamilton L; Lonsdale E; Leeder J; Brooksby A; Cavill C; Berry-Jenkins J; Boyle C; Bond D; Sengupta R;
Rheumatology (Oxford); 2018 Apr; 57(4):619-624. PubMed ID: 29272541
[TBL] [Abstract][Full Text] [Related]
31. Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis.
Bekele DI; Cheng E; Reimold A; Geier C; Ganuthula K; Walsh JA; Clegg DO; Dubreuil M; Kaushik P; Ng B; Chang E; Duong R; Park J; Kerr GS
Rheumatol Int; 2022 Nov; 42(11):1925-1937. PubMed ID: 34724089
[TBL] [Abstract][Full Text] [Related]
32. Current evidence of the management of undifferentiated spondyloarthritis: a systematic literature review.
De La Mata J; Maese J; Martinez JA; Rosario P; Loza E
Semin Arthritis Rheum; 2011 Apr; 40(5):421-9, 429.e1-3. PubMed ID: 20832101
[TBL] [Abstract][Full Text] [Related]
33. Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study.
Lubrano E; Massimo Perrotta F; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
J Rheumatol; 2016 Aug; 43(8):1541-6. PubMed ID: 27252428
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
Akiyama M; Kaneko Y; Kondo H; Takeuchi T
Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
[TBL] [Abstract][Full Text] [Related]
35. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
Nissen M; Delcoigne B; Di Giuseppe D; Jacobsson L; Hetland ML; Ciurea A; Nekvindova L; Iannone F; Akkoc N; Sokka-Isler T; Fagerli KM; Santos MJ; Codreanu C; Pombo-Suarez M; Rotar Z; Gudbjornsson B; van der Horst-Bruinsma I; Loft AG; Möller B; Mann H; Conti F; Yildirim Cetin G; Relas H; Michelsen B; Avila Ribeiro P; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Askling J; Glintborg B; Lindström U
Rheumatology (Oxford); 2022 Nov; 61(12):4741-4751. PubMed ID: 35323903
[TBL] [Abstract][Full Text] [Related]
36. The long-term persistence of tumor necrosis factor inhibitors in patients with moderate to severe immune-mediated rheumatic diseases: A nation-wide, population-based real-world study.
Huang JY; Leong PY; Ker A; Chen HH; Wei JC
Int J Rheum Dis; 2022 Nov; 25(11):1295-1305. PubMed ID: 35975402
[TBL] [Abstract][Full Text] [Related]
37. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
[TBL] [Abstract][Full Text] [Related]
38. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of tumor necrosis factor α blockers in early axial spondyloarthritis: data from the DESIR cohort.
Moltó A; Paternotte S; Claudepierre P; Breban M; Dougados M
Arthritis Rheumatol; 2014 Jul; 66(7):1734-44. PubMed ID: 24623678
[TBL] [Abstract][Full Text] [Related]
40. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
